Mepolizumab Reduces Steroid Use in COPD
Summary
A pooled analysis of three phase 3 trials found 29% to 36% lower annual corticosteroid exposure with mepolizumab, with greater reductions at higher eosinophil counts. Medscape Medical News
Description from Medscape.
Who is covering this
-
Mepolizumab Reduces Steroid Use in COPD
A pooled analysis of three phase 3 trials found 29% to 36% lower annual corticosteroid exposure with mepolizumab, with greater reductions at higher eosinophil counts. Medscape Medical News
Comments
Comments need JavaScript.